LPRS3
MCID: LPR021
MIFTS: 67

Leprosy 3 (LPRS3)

Categories: Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Leprosy 3

MalaCards integrated aliases for Leprosy 3:

Name: Leprosy 3 56 29 6
Leprosy 56 12 74 25 58 43 15 17 71
Leprosy, Susceptibility to 56 13
Infection Due to Mycobacterium Leprae 25
Leprosy, Susceptibility to, 3 56
Hansen's Disease 25
Leprosy, Type 3 39
Hansen Disease 25
Lprs3 56

Characteristics:

Orphanet epidemiological data:

58
leprosy
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Worldwide); Age of onset: All ages; Age of death: any age;

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
see for a discussion on leprosy susceptibility



Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infertility disorders
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1024
OMIM 56 246300
ICD9CM 34 030 030.9
MeSH 43 D007918
NCIt 49 C84824
SNOMED-CT 67 81004002
ICD10 32 A30 A30.9
MESH via Orphanet 44 D007918
UMLS via Orphanet 72 C0023343
Orphanet 58 ORPHA548
MedGen 41 C1968668
SNOMED-CT via HPO 68 258211005 263681008
UMLS 71 C0023343

Summaries for Leprosy 3

Genetics Home Reference : 25 Leprosy, also called Hansen disease, is a disorder known since ancient times. It is caused by bacteria called Mycobacterium leprae and is contagious, which means that it can be passed from person to person. It is usually contracted by breathing airborne droplets from affected individuals' coughs and sneezes, or by coming into contact with their nasal fluids. However, it is not highly transmissible, and approximately 95 percent of individuals who are exposed to Mycobacterium leprae never develop leprosy. The infection can be contracted at any age, and signs and symptoms can take anywhere from several months to 20 years to appear. Mycobacterium leprae Mycobacterium leprae Leprosy affects the skin and the peripheral nerves, which connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, and heat. Most affected individuals have areas of skin damage (cutaneous lesions) and problems with nerve function (peripheral neuropathy); however, the severity and extent of the problems vary widely. Leprosy occurs on a spectrum, in which the most severe form is called multibacillary or lepromatous, and the least severe form is called paucibacillary or tuberculoid. Patterns of signs and symptoms intermediate between these forms are sometimes called borderline forms. Multibacillary leprosy usually involves a large number of cutaneous lesions, including both surface damage and lumps under the skin (nodules). The moist tissues that line body openings such as the eyelids and the inside of the nose and mouth (mucous membranes) can also be affected, which can lead to vision loss, destruction of nasal tissue, or impaired speech. Some affected individuals have damage to internal organs and tissues. The nerve damage that occurs in multibacillary leprosy often results in a lack of sensation in the hands and feet. Repeated injuries that go unnoticed and untreated because of this lack of sensation can lead to reabsorption of affected fingers or toes by the body, resulting in the shortening or loss of these digits. Paucibacillary leprosy typically involves a small number of surface lesions on the skin. There is generally loss of sensation in these areas, but the other signs and symptoms that occur in multibacillary leprosy are less likely to develop in this form of the disorder. In any form of leprosy, episodes called reactions can occur, and can lead to further nerve damage. These episodes can include reversal reactions, which involve pain and swelling of the skin lesions and the nerves in the hands and feet. People with the more severe forms of leprosy can develop a type of reaction called erythema nodosum leprosum (ENL). These episodes involve fever and painful skin nodules. In addition, painful, swollen nerves can occur. ENL can also lead to inflammation of the joints, eyes, and the testicles in men. Leprosy has long been stigmatized because of its infectious nature and the disfigurement it can cause. This stigma can cause social and emotional problems for affected individuals. However, modern treatments can prevent leprosy from getting worse and spreading to other people. While the infection is curable, nerve and tissue damage that occurred before treatment is generally permanent.

MalaCards based summary : Leprosy 3, also known as leprosy, is related to borderline leprosy and indeterminate leprosy, and has symptoms including skin lesions, sensory loss and motor loss. An important gene associated with Leprosy 3 is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Dapsone and Rifampicin have been mentioned in the context of this disorder. Affiliated tissues include superficial peripheral nerves, skin and mucous membranes of the upper respiratory tract, and related phenotypes are abnormality of the immune system and hematopoietic system

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in superficial peripheral nerves, located in skin, located in mucous membranes of the upper respiratory tract, located in anterior chamber of the eyes, or located in testes, has material basis in Mycobacterium leprae, which is transmitted by aerosol spread from infected nasal secretions to exposed nasal and oral mucosa. The infection has symptom skin lesions, has symptom sensory loss, has symptom motor loss and has symptom eye damage.

Wikipedia : 74 Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacteria Mycobacterium... more...

More information from OMIM: 246300

Related Diseases for Leprosy 3

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1101)
# Related Disease Score Top Affiliating Genes
1 borderline leprosy 35.4 SDHD MLLT1 CD40LG CCDC122
2 indeterminate leprosy 35.2 SLC11A1 SDHD PACRG MLLT1 CD40LG CCDC122
3 buruli ulcer 33.4 SLC11A1 IL10 IFNG
4 neuritis 32.1 TNF IL10 IFNG
5 syphilis 32.0 CD8A CD40LG CD4 CCR6
6 leishmaniasis 31.8 TNF TLR2 SLC11A1 IL2 IL10 IFNG
7 iridocyclitis 31.7 TNF CD40LG CD4
8 allergic hypersensitivity disease 31.7 TNF TLR2 IL2 IL10 IFNG CD4
9 mycobacterium tuberculosis 1 31.7 TNF TLR2 SLC11A1 NOD2 IL10 IFNG
10 uveitis 31.6 TNF NOD2 IL2 IL10 IFNG
11 keratitis, hereditary 31.5 TNF TLR2 IL10 CD8A CD4 CCR6
12 peripheral nervous system disease 31.5 TNF TLR2 PRKN MLLT1 IL2 IL10
13 sarcoidosis 1 31.5 TNF SLC11A1 NOD2 IL2 IFNG CD8A
14 skin disease 31.5 TNF TLR2 IL2 IL10 IFNG CD8A
15 facial paralysis 31.5 CD8A CD40LG CD4
16 cutaneous leishmaniasis 31.5 TNF TLR2 SLC11A1 IL2 IL10 IFNG
17 chronic granulomatous disease 31.4 TNF SLC11A1 LACC1 IFNG CD40LG
18 immune deficiency disease 31.4 TNF IL2 IL10 IFNG CD40LG CD4
19 iritis 31.4 TNF NOD2 CD40LG CD4 CCR6
20 autoimmune disease 31.4 TNF SLC11A1 IL2 IL10 IFNG CD40LG
21 exanthem 31.4 TNF IL2 IL10 CD8A CD40LG CD4
22 arthritis 31.4 TNF TLR2 SLC11A1 NOD2 LACC1 IL10
23 tetanus 31.4 TNF IL2 IL10 IFNG CD40LG
24 tenosynovitis 31.3 TNF NOD2 CD40LG
25 psoriasis 31.3 TNF TLR2 NOD2 IL2 IL10 IFNG
26 filariasis 31.3 TNF TLR2 IL2 IL10 IFNG
27 dermatitis 31.2 TNF TLR2 NOD2 IL2 IL10 IFNG
28 human immunodeficiency virus type 1 31.2 TNF IL2 IL10 IFNG CD4
29 vitiligo-associated multiple autoimmune disease susceptibility 1 31.2 IL2 CD8A CD4 CCR6
30 osteomyelitis 31.2 TNF TLR2 NOD2 IL10 IFNG
31 rheumatic disease 31.2 TNF IL10 IFNG CD40LG CCR6
32 visceral leishmaniasis 31.2 TNF TLR2 SLC11A1 IL2 IL10 IFNG
33 granulomatous dermatitis 31.2 TNF NOD2 CD40LG CD4
34 secondary syphilis 31.2 CD8A CD40LG CD4
35 conjunctivitis 31.1 TNF IL2 IL10 IFNG
36 scleritis 31.1 TNF IFNG CCR6
37 norwegian scabies 31.1 CD8A CD40LG CD4
38 erythema multiforme 31.1 TNF IL2 IFNG
39 proteasome-associated autoinflammatory syndrome 1 31.1 TNF TLR2 IL10 IFNG
40 plague 31.1 TNF TLR2 IL10 CD8A CD4
41 lymphadenitis 31.1 TNF SLC11A1 NOD2 IL10 IFNG CD4
42 sporotrichosis 31.1 TNF IL10 IFNG CD40LG CD4
43 periodontitis 31.1 TNF TLR2 IL10 IFNG
44 mucocutaneous leishmaniasis 31.1 TNF IL2 IL10 IFNG CD8A CD4
45 systemic lupus erythematosus 31.0 TNF TLR2 IL2 IL10 IFNG CD8A
46 lymphopenia 31.0 IL2 IL10 IFNG CCR6
47 pfeiffer syndrome 31.0 IL2 CD8A CD40LG CD4 CCR6
48 poliomyelitis 31.0 TNF IL10 IFNG CD8A CD40LG CD4
49 filarial elephantiasis 31.0 TLR2 IL10 CD4
50 cellulitis 31.0 TNF IL10 CD8A CD40LG CD4 CCR6

Comorbidity relations with Leprosy 3 via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Leprosy 3:



Diseases related to Leprosy 3

Symptoms & Phenotypes for Leprosy 3

Human phenotypes related to Leprosy 3:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 31 HP:0002715

Symptoms via clinical synopsis from OMIM:

56
Immunology:
susceptibility to infection by mycobacterium leprae causing leprosy

Clinical features from OMIM:

246300

Symptoms:

12
  • skin lesions
  • sensory loss
  • motor loss
  • eye damage

MGI Mouse Phenotypes related to Leprosy 3:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 CCR6 CD4 CD40LG CD8A IFNG IL10
2 cellular MP:0005384 10.32 CD4 CD40LG CD8A IFNG IL10 IL2
3 homeostasis/metabolism MP:0005376 10.25 CCR6 CD4 CD40LG IFNG IL10 IL2
4 immune system MP:0005387 10.25 CCR6 CD4 CD40LG CD8A IFNG IL10
5 cardiovascular system MP:0005385 10.22 CCR6 CD40LG IFNG IL10 IL2 LRRK2
6 endocrine/exocrine gland MP:0005379 10.18 CD4 CD40LG CD8A IFNG IL10 IL2
7 mortality/aging MP:0010768 10.17 CD4 CD40LG CD8A IFNG IL10 IL2
8 digestive/alimentary MP:0005381 10.1 CD4 IFNG IL10 IL2 NOD2 SLC11A1
9 integument MP:0010771 10.02 CD4 CD40LG CD8A IFNG IL10 LRRK2
10 nervous system MP:0003631 9.9 CCR6 CD4 CD40LG CD8A IFNG IL10
11 neoplasm MP:0002006 9.86 IFNG IL10 IL2 MLLT1 SDHD SLC11A1
12 no phenotypic analysis MP:0003012 9.5 CD4 IFNG IL10 IL2 LRRK2 PRKN
13 normal MP:0002873 9.32 CCR6 CD4 CD8A IFNG IL10 LRRK2

Drugs & Therapeutics for Leprosy 3

Drugs for Leprosy 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4 80-08-0 2955
2
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
3 Antibiotics, Antitubercular Phase 4
4 Antimalarials Phase 4
5 Cytochrome P-450 CYP3A Inducers Phase 4
6 Antiparasitic Agents Phase 4
7 Antiprotozoal Agents Phase 4
8 Vitamins Phase 4
9 Vaccines Phase 4
10 Anti-Bacterial Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Immunosuppressive Agents Phase 4
13 Immunologic Factors Phase 4
14 Angiogenesis Inhibitors Phase 4
15
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
16
Amitriptyline Approved Phase 3 50-48-6 2160
17
Perphenazine Approved Phase 3 58-39-9 4748
18
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
19
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
20
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
21
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
22
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
23
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
24
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
25
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
26
Infliximab Approved Phase 3 170277-31-3
27
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
28
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
29
Norgestimate Approved, Investigational Phase 2, Phase 3 35189-28-7 6540478
30
Polyestradiol phosphate Approved Phase 2, Phase 3 28014-46-2
31
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
32
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
33
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3 50-28-2 5757
34
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
35
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
36 Tocotrienol Investigational Phase 3 6829-55-6
37 Tranquilizing Agents Phase 3
38 Narcotics Phase 3
39 Antipsychotic Agents Phase 3
40 Amitriptyline, perphenazine drug combination Phase 3
41 Analgesics Phase 3
42 Psychotropic Drugs Phase 3
43 Analgesics, Non-Narcotic Phase 3
44 Central Nervous System Depressants Phase 3
45 Analgesics, Opioid Phase 3
46 Antidepressive Agents Phase 3
47 Adrenergic Agents Phase 3
48 Antidepressive Agents, Tricyclic Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Antifungal Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
4 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
5 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Recruiting NCT03519568 Phase 4
6 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
7 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Unknown status NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
10 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
11 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
12 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Completed NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
13 A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
17 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
18 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
19 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Not yet recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
20 To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus. Unknown status NCT02023411 Phase 2 Teriparatide
21 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
22 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
23 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00162760 Phase 2 Thalidomide
24 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
25 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
26 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
27 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
28 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
29 Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia Patients of Pakistan Recruiting NCT03651102 Phase 2 Thalidomide Oral Product
30 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
31 Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease Recruiting NCT02968212 Phase 2 Clofazimine
32 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
33 A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. Terminated NCT00469703 Phase 2 Thalidomide
34 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
35 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
36 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
37 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
38 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
39 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
40 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
41 A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG. Completed NCT00654316 Phase 1
42 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
43 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis. Completed NCT00456183 Phase 1
44 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV Completed NCT00395720 Phase 1
45 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
46 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
47 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Unknown status NCT01751503
48 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
49 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
50 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717

Search NIH Clinical Center for Leprosy 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Cochrane evidence based reviews: leprosy

Genetic Tests for Leprosy 3

Genetic tests related to Leprosy 3:

# Genetic test Affiliating Genes
1 Leprosy 3 29 TLR2

Anatomical Context for Leprosy 3

The Foundational Model of Anatomy Ontology organs/tissues related to Leprosy 3:

19
Superficial Peripheral Nerves, Skin, Mucous Membranes Of The Upper Respiratory Tract, Anterior Chamber Of The Eyes, Testes

MalaCards organs/tissues related to Leprosy 3:

40
Skin, Testes, T Cells, Eye, Bone, Liver, Monocytes

Publications for Leprosy 3

Articles related to Leprosy 3:

(show top 50) (show all 20002)
# Title Authors PMID Year
1
No involvement of non-synonymous TLR2 polymorphisms in Japanese leprosy patients. 56 6 61
19111445 2009
2
TLR2 Arg677Trp polymorphism in leprosy: revisited. 61 56 6
15726416 2005
3
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. 61 56 6
12646604 2003
4
Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. 6 56 61
11476982 2001
5
Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. 61 6
19456232 2009
6
Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. 56 61
18177245 2008
7
The polymorphism P315L of human toll-like receptor 1 impairs innate immune sensing of microbial cell wall components. 6
17475868 2007
8
A family of human receptors structurally related to Drosophila Toll. 56
9435236 1998
9
A systematic review on Piper longum L.: Bridging traditional knowledge and pharmacological evidence for future translational research. 61
31568819 2020
10
Frequent testicular involvement in multibacillary leprosy. 61
31634613 2020
11
Intracellular Mycobacterium leprae Utilizes Host Glucose as a Carbon Source in Schwann Cells. 61
31848273 2019
12
Tuberculosis control activities in the private and public health sectors of Kenya from 2013 to 2017: how do they compare? 61
31334760 2019
13
Raman spectroscopy reveals distinct differences between two closely related bacterial strains, Mycobacterium indicus pranii and Mycobacterium intracellulare. 61
31732785 2019
14
WQ-3810 inhibits DNA gyrase activity in ofloxacin-resistant Mycobacterium leprae. 61
31839561 2019
15
Epitope imprinting of Mycobacterium leprae bacteria via molecularly imprinted nanoparticles using multiple monomers approach. 61
31539652 2019
16
Recombinant polypeptide of Mycobacterium leprae as a potential tool for serological detection of leprosy. 61
31848766 2019
17
Report on an unusual case of leprosy from Germany: just an exception of the rule? 61
31456174 2019
18
Protocol, rationale and design of PEOPLE (Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar): a cluster randomized trial on effectiveness of different modalities of implementation of post-exposure prophylaxis of leprosy contacts. 61
31805862 2019
19
Case Report: Nasal Myiasis in an Elderly Patient with Atrophic Rhinitis Ozenosa and Facial Sequelae of Leprosy. 61
31802737 2019
20
Current updates on dental perspectives of leprosy - Revisited. 61
31813526 2019
21
A neglected illness still present nowadays: Tuberculoid leprosy. 61
31813644 2019
22
Strategy That May Be Tried in Military Regime-Leprosy. 61
31665397 2019
23
Diet and nutrition: An important risk factor in leprosy. 61
31493502 2019
24
Histioid Leprosy a Rare Variant: First Report in Ecuador. 61
31395272 2019
25
Nevus depigmentosus: review of a mark of distinction. 61
30801693 2019
26
Epidemiological aspects of leprosy. 61
31806242 2019
27
Chronic aspects of leprosy-neglected but important. 61
30715525 2019
28
Archival, paleopathological and aDNA-based techniques in leprosy research and the case of Father Petrus Donders at the Leprosarium 'Batavia', Suriname. 61
31430635 2019
29
Comparison of quality of life evaluated by SF-36 and DLQI in multibacillary and paucibacillary leprosy patients from Sao Paulo, Brazil. 61
31148144 2019
30
Dr E W Price, the discoverer of podoconiosis. 61
31735101 2019
31
Isolation of Mycobacterium lepromatosis and Development of Molecular Diagnostic Assays to Distinguish M. leprae and M. lepromatosis. 61
31732729 2019
32
Serological and molecular detection of infection with Mycobacterium leprae in Brazilian six banded armadillos (Euphractus sexcinctus). 61
31775113 2019
33
Late reversal reaction with resistant Mycobacterium leprae: an emerging paradigm. 61
31707970 2019
34
LRRK2 regulation of immune-pathways and inflammatory disease. 61
31769472 2019
35
Use of Customized Bacteriophages in the Treatment of Chronic Nonhealing Wounds: A Prospective Study. 61
31752578 2019
36
Post-translational modification of Parkin and its research progress in cancer. 61
31753025 2019
37
Knowledge on leprosy and its management among primary healthcare providers in two districts of Bangladesh. 61
31679517 2019
38
Utility of multiplex PCR for early diagnosis and household contact surveillance for leprosy. 61
31285121 2019
39
Oral manifestation in leprosy: A cross-sectional study of 100 cases with literature review. 61
31803674 2019
40
Correlation of Dermoscopic and Histopathologic Patterns in Leprosy - A Pilot Study. 61
31807445 2019
41
Pandit Kriparam Sarma: A Brief Account of an Unsung and Unmourned Leprosy Curer. 61
31807469 2019
42
Ulcers in leprosy patients, an unrecognized clinical manifestation: a report of 8 cases. 61
31783808 2019
43
Pearls & Oy-sters: Supraorbital neuralgia in lepromatus leprosy masquerading as SUNA. 61
31712372 2019
44
Leprosy in the North and Northeast regions of Brazil: an integrated spatiotemporal approach. 61
31713982 2019
45
Lack of evidence for the presence of leprosy bacilli in red squirrels from North-West Europe. 61
31733134 2019
46
Quantitative PCR for leprosy diagnosis and monitoring in household contacts: A follow-up study, 2011-2018. 61
31723144 2019
47
Diagnostic accuracy of tests for leprosy: a systematic review and meta-analysis. 61
31158516 2019
48
Effectiveness of single-dose rifampicin after BCG vaccination to prevent leprosy in close contacts of patients with newly diagnosed leprosy: A cluster randomized controlled trial. 61
31499206 2019
49
Spatial distribution and temporal trends of leprosy in Uganda, 2012-2016: a retrospective analysis of public health surveillance data. 61
31783799 2019
50
Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study. 61
31784594 2019

Variations for Leprosy 3

ClinVar genetic disease variations for Leprosy 3:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TLR2 NM_003264.5(TLR2):c.2029C>T (p.Arg677Trp)SNV risk factor 6663 rs121917864 4:154626088-154626088 4:153704936-153704936

Copy number variations for Leprosy 3 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 255081 9 72339785 73251640 Duplication TRPM3 Leprosy

Expression for Leprosy 3

Search GEO for disease gene expression data for Leprosy 3.

Pathways for Leprosy 3

Pathways related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TNF TLR2 SLC11A1 PRKN NOD2 IL2
2
Show member pathways
13.32 TNF NOD2 IL2 IL10 IFNG CD40LG
3
Show member pathways
13.08 TNF TLR2 NOD2 IL2 IL10 IFNG
4
Show member pathways
12.78 TNF LRRK2 IL2 IL10 IFNG CD8A
5
Show member pathways
12.61 TNF IL2 IL10 IFNG CD40LG CD4
6
Show member pathways
12.56 TNF IL2 IL10 IFNG CD4
7
Show member pathways
12.56 TNF TLR2 NOD2 IL2 IL10 IFNG
8 12.52 TNF TLR2 IL2 IL10 IFNG CD8A
9
Show member pathways
12.4 TNF TLR2 IL2 IL10 IFNG CD8A
10
Show member pathways
12.29 TNF IL2 IL10 CCR6
11
Show member pathways
12.29 TLR2 SLC11A1 CD4 CCR6
12
Show member pathways
12.23 TNF TLR2 IL10 IFNG CD40LG
13 12.19 TNF TLR2 NOD2 IL10 IFNG
14
Show member pathways
12 TNF TLR2 IL2 IL10 IFNG CD4
15
Show member pathways
11.96 IL2 IFNG CD8A CD4
16 11.89 TNF TLR2 IL10 IFNG
17 11.86 TNF IL2 IL10 IFNG CD8A CD4
18
Show member pathways
11.75 TNF IL2 IFNG CD40LG
19 11.7 TNF IL2 IL10 IFNG
20
Show member pathways
11.62 TNF IL2 IFNG CD40LG
21
Show member pathways
11.6 TNF IL2 IFNG CD8A
22 11.55 IL10 CD40LG CD4
23 11.53 TNF IL2 IFNG
24 11.5 TNF TLR2 IFNG
25 11.49 TNF IL2 IFNG
26 11.47 TNF TLR2 IL10 IFNG CD40LG
27 11.46 IL2 IL10 IFNG CD4
28 11.38 CD8A CD40LG CD4
29 11.36 TNF IL10 IFNG
30 11.31 IL2 IFNG CD40LG
31 11.3 TNF IL2 IL10 IFNG CD8A CD4
32 11.22 IL2 IFNG CD4
33 11.18 IL2 IL10 IFNG
34 11.07 TNF IL2 IL10 IFNG CD8A CD4
35 11.02 TNF IL2 IL10 IFNG CD4

GO Terms for Leprosy 3

Cellular components related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.46 TNF TLR2 LRRK2 CD4
2 external side of plasma membrane GO:0009897 9.35 TNF CD8A CD40LG CD4 CCR6
3 cell surface GO:0009986 9.1 TNF TLR2 NOD2 CD40LG CD4 CCR6

Biological processes related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 TNF TLR2 SLC11A1 PRKN NOD2 IL2
2 positive regulation of gene expression GO:0010628 10.05 TNF TLR2 SLC11A1 PRKN IFNG
3 inflammatory response GO:0006954 9.98 TNF TLR2 SLC11A1 IL10 CD40LG
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.89 TNF PRKN NOD2 CD4
5 negative regulation of protein phosphorylation GO:0001933 9.85 PRKN LRRK2 IL2
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNF TLR2 NOD2 CD40LG
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL2 IFNG
8 cellular response to organic cyclic compound GO:0071407 9.82 TNF NOD2 LRRK2
9 positive regulation of MAP kinase activity GO:0043406 9.81 TNF NOD2 LRRK2
10 positive regulation of T cell proliferation GO:0042102 9.8 IL2 CD40LG CD4
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 TNF TLR2 NOD2
12 positive regulation of interleukin-6 production GO:0032755 9.79 TNF TLR2 NOD2
13 humoral immune response GO:0006959 9.77 TNF IFNG CCR6
14 positive regulation of phagocytosis GO:0050766 9.73 TNF SLC11A1 IFNG
15 positive regulation of interferon-gamma production GO:0032729 9.72 TNF SLC11A1 IL2
16 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IFNG
17 negative regulation of amyloid-beta clearance GO:1900222 9.67 TNF IFNG
18 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IFNG
19 positive regulation of programmed cell death GO:0043068 9.66 TNF LRRK2
20 cellular response to manganese ion GO:0071287 9.65 PRKN LRRK2
21 endothelial cell apoptotic process GO:0072577 9.64 TNF IL10
22 microglial cell activation GO:0001774 9.63 TNF TLR2 IFNG
23 protein localization to mitochondrion GO:0070585 9.61 PRKN LRRK2
24 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.61 SLC11A1 NOD2
25 positive regulation of interleukin-8 production GO:0032757 9.61 TNF TLR2 NOD2
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 TNF IL10
27 positive regulation of interleukin-12 production GO:0032735 9.58 TLR2 IFNG CD40LG
28 regulation of immunoglobulin secretion GO:0051023 9.57 TNF CD40LG
29 positive regulation of protein phosphorylation GO:0001934 9.55 TNF LRRK2 IL2 IFNG CD4
30 cytokine secretion involved in immune response GO:0002374 9.52 TLR2 NOD2
31 regulation of synaptic vesicle transport GO:1902803 9.51 PRKN LRRK2
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 TNF IFNG
33 receptor biosynthetic process GO:0032800 9.48 TNF IL10
34 positive regulation of interleukin-10 production GO:0032733 9.43 TLR2 NOD2 CD40LG
35 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 TNF IFNG
36 positive regulation of nitrogen compound metabolic process GO:0051173 9.32 TNF IFNG
37 immune response GO:0006955 9.32 TNF TLR2 SLC11A1 IL2 IL10 IFNG
38 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.26 TLR2 NOD2 LRRK2 IFNG

Molecular functions related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp70 protein binding GO:0030544 9.13 PRKN PACRG NOD2
2 cytokine activity GO:0005125 9.02 TNF IL2 IL10 IFNG CD40LG

Sources for Leprosy 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....